Skip to main content

Tri Locum Partners LP

13F filer · CIK 0001826434
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$813MU.S. long equity reported on 13F
Positions194 new · 2 closed
Net flow last quarter+$37.1MBuys minus sells
Top 10 positions weight80.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202619 positions
JNJJohnson & Johnson$108M13.27%0.02%+2.5%Q4 2020
VRTXVertex Pharmaceuticals Inc / Ma$100M12.33%0.08%+56.1%Q2 2023
LLYELI LILLY & Co$91.8M11.29%0.01%+23.9%Q4 2020
ASNDAscendis Pharma A/S$69M8.49%0.42%+1.3%Q4 2022
DXCMDexcom Inc$55.3M6.80%0.22%+17.5%Q2 2023
AXSMAxsome Therapeutics, Inc.$53.7M6.60%0.42%+253.1%Q4 2022
JAZZJazz Pharmaceuticals plc$53.4M6.57%0.35%+39.7%Q1 2021
ELVNEnliven Therapeutics, Inc.$44M5.41%1.18%NewQ2 2026
ARGXArgenx SE$38.6M4.75%0.07%+31.5%Q2 2021
MDGLMadrigal Pharmaceuticals, Inc.$36.7M4.51%0.30%-33.9%Q4 2022
RVMDRevolution Medicines, Inc.$28.4M3.50%0.07%Not reportedQ1 2022
UTHRUNITED THERAPEUTICS Corp$25.5M3.13%0.11%-33.2%Q3 2021
TEVATeva Pharmaceutical Industries Ltd$25.3M3.11%0.06%-26.9%Q3 2022
TARSTarsus Pharmaceuticals, Inc.$20.7M2.54%0.76%+30.0%Q2 2025
ISRGIntuitive Surgical Inc$19.1M2.35%0.01%-68.7%Q3 2023
CYTKCytokinetics Inc$16.5M2.03%0.16%Not reportedQ4 2021
DNTHDianthus Therapeutics, Inc.$11.8M1.45%0.22%-17.1%Q3 2025
BBNXBeta Bionics, Inc.$7.73M0.95%1.10%NewQ2 2026
DFTXDefinium Therapeutics, Inc.$7.67M0.94%0.12%-55.9%Q1 2026
Q1 2026Reported May 18, 202617 positions
JNJJohnson & Johnson$101M14.22%0.02%-31.3%Q4 2020
ISRGIntuitive Surgical Inc$70.6M9.91%0.04%Not reportedQ3 2023
TMOThermo Fisher Scientific Inc.$65.1M9.13%0.04%Not reportedQ1 2023
ASNDAscendis Pharma A/S$58.4M8.20%0.41%-3.7%Q4 2022
VRTXVertex Pharmaceuticals Inc / Ma$57.7M8.10%0.05%Not reportedQ2 2023
LLYELI LILLY & Co$56.8M7.98%0.01%-2.4%Q4 2020
MDGLMadrigal Pharmaceuticals, Inc.$54.1M7.59%0.45%+20.1%Q4 2022
DXCMDexcom Inc$43.8M6.15%0.18%+65.6%Q2 2023
UTHRUNITED THERAPEUTICS Corp$41.7M5.86%0.17%-41.8%Q3 2021
NUVLNuvalent, Inc.$31.6M4.44%9.86%+0.4%Q3 2023
TEVATeva Pharmaceutical Industries Ltd$30.8M4.32%0.09%-28.9%Q3 2022
JAZZJazz Pharmaceuticals plc$30M4.21%0.26%Not reportedQ1 2021
ARGXArgenx SE$23.1M3.24%0.05%-16.0%Q2 2021
TARSTarsus Pharmaceuticals, Inc.$17.7M2.49%0.59%Not reportedQ2 2025
DNTHDianthus Therapeutics, Inc.$12.2M1.71%0.27%-76.6%Q3 2025
AXSMAxsome Therapeutics, Inc.$10.5M1.47%0.12%-69.2%Q4 2022
DFTXDefinium Therapeutics, Inc.$6.99M0.98%0.36%NewQ1 2026
Q4 2025Reported Feb 17, 202615 positions
JNJJohnson & Johnson$125M16.21%0.03%+99.2%Q4 2020
DHRDanaher Corp$79.4M10.31%0.05%NewQ4 2025
LLYELI LILLY & Co$68M8.83%0.01%Not reportedQ4 2020
UTHRUNITED THERAPEUTICS Corp$58.9M7.65%0.28%-1.0%Q3 2021
ASNDAscendis Pharma A/S$56.5M7.34%0.43%+51.6%Q4 2022
MDGLMadrigal Pharmaceuticals, Inc.$50.1M6.50%0.38%+27.1%Q4 2022
BSXBoston Scientific Corp$49.6M6.44%0.04%NewQ4 2025
TEVATeva Pharmaceutical Industries Ltd$44.8M5.82%0.12%Not reportedQ3 2022
IONSIonis Pharmaceuticals Inc$44.1M5.72%0.34%NewQ4 2025
VERAVera Therapeutics, Inc.$40.8M5.30%1.26%-32.3%Q2 2023
AXSMAxsome Therapeutics, Inc.$36.8M4.78%0.40%-31.0%Q4 2022
ARGXArgenx SE$31.7M4.11%0.06%-13.3%Q2 2021
NUVLNuvalent, Inc.$30.9M4.01%9.82%Not reportedQ3 2023
DXCMDexcom Inc$28M3.63%0.11%Not reportedQ2 2023
DNTHDianthus Therapeutics, Inc.$25.6M3.33%1.44%+240.4%Q3 2025
Q3 2025Reported Nov 14, 202518 positions
JNJJohnson & Johnson$56.2M12.91%0.01%Not reportedQ4 2020
UTHRUNITED THERAPEUTICS Corp$51.2M11.77%0.28%Not reportedQ3 2021
MRKMerck & Co., Inc.$37.5M8.62%0.02%Not reportedQ4 2020
AXSMAxsome Therapeutics, Inc.$35.5M8.16%0.58%+85.1%Q4 2022
ASNDAscendis Pharma A/S$34.8M7.99%0.29%+18.4%Q4 2022
VERAVera Therapeutics, Inc.$34.6M7.95%1.86%+188.1%Q2 2023
ARGXArgenx SE$32M7.36%0.07%-9.2%Q2 2021
MDGLMadrigal Pharmaceuticals, Inc.$31.1M7.14%0.30%-30.8%Q4 2022
SLNOSoleno Therapeutics Inc$30.5M7.00%0.84%+56.0%Q1 2025
ABBVAbbVie Inc.$20.8M4.77%0.01%+61.0%Q4 2020
KRROKorro Bio, Inc.$16.2M3.72%3.59%+142.1%Q2 2024
XENEXenon Pharmaceuticals Inc.$14.7M3.38%0.47%Not reportedQ3 2021
AVDLAvadel Pharmaceuticals PLC$11.1M2.54%0.75%-28.6%Q1 2021
STVNStevanato Group S.p.A.$8.57M1.97%0.11%Not reportedQ4 2021
DNTHDianthus Therapeutics, Inc.$7.2M1.65%0.43%NewQ3 2025
TARSTarsus Pharmaceuticals, Inc.$7.09M1.63%0.28%-32.9%Q2 2025
PRAXPraxis Precision Medicines, Inc.$4.03M0.93%0.36%-61.1%Q4 2022
BHVNBiohaven Ltd.$2.24M0.51%0.14%-45.0%Q4 2020
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.